肾衰竭患者肺淤血的检测与治疗
综述指出肺超声可可靠评估肾衰竭患者肺水,该人群无症状中重度肺淤血高发且与生物阻抗测得液体过多仅弱相关,肺淤血与死亡风险呈剂量依赖相关;LUST试验中肺超声指导治疗可安全缓解肺淤血但未显著降低复合终点风险,事后分析显示可减少急性心衰和心血管事件复发。
要点
- 肺超声是经过验证的技术,可在临床实践中可靠估计肺水。
- 肾衰竭患者无症状中重度肺淤血患病率高,与生物阻抗测得的液体过多仅弱相关。
- LUST试验中肺超声指导治疗安全缓解肺淤血,但未显著降低死亡、非致死性心肌梗死和失代偿性心衰复合终点风险。
核心结论
- 肺超声指导治疗可安全缓解肾衰竭患者的肺淤血,但未显著降低死亡、非致死性心肌梗死和失代偿性心衰的复合终点风险。
- LUST试验事后分析显示,使用肺超声可降低急性心衰反复发作和心血管事件反复发生的风险。
- 在透析前慢性肾脏病患者中明确肺淤血的流行病学特征是公共卫生优先事项。
研究设计与样本
- 综述总结肾衰竭患者肺淤血检测与治疗的相关研究,包括LUST试验及其事后分析,并引用三项心力衰竭患者试验的结果。
主要发现
- 肾衰竭患者无症状中重度肺淤血患病率高,且该改变与生物阻抗光谱测得的液体过多仅弱相关。
- 肺淤血与死亡风险呈剂量依赖相关。
- LUST试验中肺超声指导的治疗策略安全缓解肺淤血,但未显著降低包括死亡、非致死性心肌梗死和失代偿性心衰的复合终点风险。
- LUST试验事后分析显示,使用肺超声降低急性心衰反复发作和心血管事件反复发生的风险,与三项心力衰竭患者试验结果一致。
局限性
- LUST试验中肺超声指导治疗未能显著降低复合终点风险。
- 肺淤血与生物阻抗测得的液体过多仅弱相关。
- 需在透析前慢性肾脏病人群中开展特定试验,并在肾衰竭患者中开展额外试验,以确定无症状阶段针对肺淤血治疗是否可改善心血管预后。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fluid overload is a common complication in patients with CKD, particularly patients with kidney failure, a population with a very high risk for pulmonary edema. Lung ultrasound is now a well-validated technique that allows for reliable estimates of lung water in clinical practice. Several studies in patients with kidney failure documented a high prevalence of asymptomatic lung congestion of moderate to severe degree in this population, and this alteration was only weakly related with fluid excess as measured by bioimpedance spectroscopy. Furthermore, in these studies, lung congestion correlated in a dose-dependent fashion with death risk. In the Lung Water by Ultra-Sound Guided Treatment to Prevent Death and Cardiovascular Complications in High Risk Kidney Failure Patients with Cardiomyopathy (LUST) trial, a treatment strategy guided by lung ultrasound safely relieved lung congestion but failed to significantly reduce the risk for a combined end point including death, nonfatal myocardial infarction, and decompensated heart failure. However, in line with three trials in patients with heart failure, a post hoc analysis of the LUST trial showed that the use of lung ultrasound reduces the risk for repeated episodes of acute heart failure and repeated cardiovascular events. Given the high cardiovascular risk of pulmonary edema in patients with predialysis CKD, defining the epidemiology of lung congestion in this population is a public health priority. Specific trials in this population and additional trials in patients with kidney failure will establish whether targeting lung congestion at an asymptomatic phase may improve the severe cardiovascular prognosis of both patients predialysis and patients on dialysis.
引用
- Zoccali C, Mallamaci F, Picano E, et al. Detecting and Treating Lung Congestion with Kidney Failure. Clin J Am Soc Nephrol. 2022. PMID: 35140128. doi:10.2215/CJN.14591121
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。